vs
Chatham Lodging Trust（CLDT）与Day One Biopharmaceuticals, Inc.（DAWN）财务数据对比。点击上方公司名可切换其他公司
Chatham Lodging Trust的季度营收约是Day One Biopharmaceuticals, Inc.的1.7倍（$67.5M vs $39.8M），Chatham Lodging Trust净利率更高（1.1% vs -49.6%，领先50.6%），Chatham Lodging Trust同比增速更快（-1.6% vs -57.6%）
查塔姆住宿信托是一家专注于投资、持有及运营高端长住型和精选服务类酒店物业的房地产投资信托，主要布局美国高需求的城市及城郊市场，服务商务与休闲旅客群体，追求长期稳定的现金流收益。
Day One Biopharmaceuticals是一家临床阶段生物制药公司，专注于为患有基因驱动型癌症的儿童及年轻成人患者开发精准靶向肿瘤疗法，推进创新候选药物研发，满足相关群体未被覆盖的医疗需求，主要在美国市场开展业务。
CLDT vs DAWN — 直观对比
营收规模更大
CLDT
是对方的1.7倍
$39.8M
营收增速更快
CLDT
高出55.9%
-57.6%
净利率更高
CLDT
高出50.6%
-49.6%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $67.5M | $39.8M |
| 净利润 | $725.0K | $-19.7M |
| 毛利率 | — | — |
| 营业利润率 | 2.4% | -60.9% |
| 净利率 | 1.1% | -49.6% |
| 营收同比 | -1.6% | -57.6% |
| 净利润同比 | — | -153.3% |
| 每股收益（稀释后） | — | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDTDAWN
| Q1 26 | $67.5M | — | ||
| Q4 25 | $67.7M | — | ||
| Q3 25 | $78.4M | $39.8M | ||
| Q2 25 | $80.3M | $33.9M | ||
| Q1 25 | $68.6M | $30.8M | ||
| Q4 24 | $75.1M | — | ||
| Q3 24 | $87.2M | $93.8M | ||
| Q2 24 | $86.5M | — |
净利润CLDTDAWN
| Q1 26 | $725.0K | — | ||
| Q4 25 | $4.6M | — | ||
| Q3 25 | $3.5M | $-19.7M | ||
| Q2 25 | $5.4M | $-30.3M | ||
| Q1 25 | $1.5M | $-36.0M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $4.3M | $37.0M | ||
| Q2 24 | $6.8M | — |
毛利率CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 40.7% | — | ||
| Q3 24 | 44.7% | — | ||
| Q2 24 | 46.1% | — |
营业利润率CLDTDAWN
| Q1 26 | 2.4% | — | ||
| Q4 25 | 15.9% | — | ||
| Q3 25 | 12.7% | -60.9% | ||
| Q2 25 | 14.8% | -103.1% | ||
| Q1 25 | 12.1% | -133.5% | ||
| Q4 24 | 7.5% | — | ||
| Q3 24 | 14.3% | 31.6% | ||
| Q2 24 | 16.3% | — |
净利率CLDTDAWN
| Q1 26 | 1.1% | — | ||
| Q4 25 | 6.8% | — | ||
| Q3 25 | 4.5% | -49.6% | ||
| Q2 25 | 6.7% | -89.4% | ||
| Q1 25 | 2.2% | -117.0% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | 4.9% | 39.5% | ||
| Q2 24 | 7.9% | — |
每股收益（稀释后）CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | $0.05 | — | ||
| Q3 25 | $0.03 | $-0.19 | ||
| Q2 25 | $0.07 | $-0.29 | ||
| Q1 25 | $-0.01 | $-0.35 | ||
| Q4 24 | $-0.08 | — | ||
| Q3 24 | $0.05 | $0.38 | ||
| Q2 24 | $0.10 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.7M | $451.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $722.9M | $450.9M |
| 总资产 | $1.2B | $513.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLDTDAWN
| Q1 26 | $13.7M | — | ||
| Q4 25 | $24.4M | — | ||
| Q3 25 | $13.2M | $451.6M | ||
| Q2 25 | $17.2M | $453.1M | ||
| Q1 25 | $18.6M | $473.0M | ||
| Q4 24 | $20.2M | — | ||
| Q3 24 | $19.3M | $558.4M | ||
| Q2 24 | $10.6M | — |
总债务CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | $338.9M | — | ||
| Q3 25 | $338.8M | — | ||
| Q2 25 | $351.2M | — | ||
| Q1 25 | $381.1M | — | ||
| Q4 24 | $406.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CLDTDAWN
| Q1 26 | $722.9M | — | ||
| Q4 25 | $740.8M | — | ||
| Q3 25 | $749.4M | $450.9M | ||
| Q2 25 | $754.1M | $460.8M | ||
| Q1 25 | $754.7M | $479.5M | ||
| Q4 24 | $758.2M | — | ||
| Q3 24 | $765.3M | $555.5M | ||
| Q2 24 | $766.5M | — |
总资产CLDTDAWN
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $513.8M | ||
| Q2 25 | $1.2B | $519.0M | ||
| Q1 25 | $1.2B | $534.4M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | $600.8M | ||
| Q2 24 | $1.3B | — |
负债/权益比CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | $64.1M | — | ||
| Q3 25 | $25.6M | $-5.8M | ||
| Q2 25 | $22.1M | $-24.8M | ||
| Q1 25 | $4.2M | $-59.0M | ||
| Q4 24 | $73.8M | — | ||
| Q3 24 | $28.8M | $50.8M | ||
| Q2 24 | $25.2M | — |
自由现金流CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-24.8M | ||
| Q1 25 | — | $-59.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $50.0M | ||
| Q2 24 | — | — |
自由现金流率CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -73.2% | ||
| Q1 25 | — | -192.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | — |
资本支出强度CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.8% | ||
| Q2 24 | — | — |
现金转化率CLDTDAWN
| Q1 26 | — | — | ||
| Q4 25 | 13.90× | — | ||
| Q3 25 | 7.24× | — | ||
| Q2 25 | 4.10× | — | ||
| Q1 25 | 2.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.78× | 1.37× | ||
| Q2 24 | 3.68× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLDT
| Room | $61.2M | 91% |
| Other | $4.7M | 7% |
| Food and beverage | $1.6M | 2% |
DAWN
| Products | $38.5M | 97% |
| License Agreement With Ipsen Pharma Sas | $1.3M | 3% |
